Allogene Therapeutics (ALLO) Enterprise Value (2019 - 2025)
Historic Enterprise Value for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to -$252.2 million.
- Allogene Therapeutics' Enterprise Value rose 1350.3% to -$252.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$252.2 million, marking a year-over-year increase of 1350.3%. This contributed to the annual value of -$292.5 million for FY2024, which is 3481.66% up from last year.
- According to the latest figures from Q3 2025, Allogene Therapeutics' Enterprise Value is -$252.2 million, which was up 1350.3% from -$273.1 million recorded in Q2 2025.
- Allogene Therapeutics' Enterprise Value's 5-year high stood at -$252.2 million during Q3 2025, with a 5-year trough of -$699.6 million in Q1 2021.
- Its 5-year average for Enterprise Value is -$438.6 million, with a median of -$457.3 million in 2021.
- Data for Allogene Therapeutics' Enterprise Value shows a peak YoY increase of 4476.43% (in 2021) and a maximum YoY decrease of 4192.5% (in 2021) over the last 5 years.
- Allogene Therapeutics' Enterprise Value (Quarter) stood at -$457.3 million in 2021, then decreased by 13.12% to -$517.3 million in 2022, then rose by 13.27% to -$448.7 million in 2023, then soared by 34.82% to -$292.5 million in 2024, then increased by 13.77% to -$252.2 million in 2025.
- Its Enterprise Value was -$252.2 million in Q3 2025, compared to -$273.1 million in Q2 2025 and -$280.0 million in Q1 2025.